Vitranu
Columbus, US · Founded 2020 · Delaware corporation · 2 known investors
Vitranu develops biomaterial and biologic technologies for ophthalmic applications, particularly focused on retinal and vitreoretinal diseases. The company brings medical devices and therapeutics to market for eye care professionals and patients.
BiotechDeep TechHealthtechMedical Devices
Founders & leadership
JB
John BlackCEO
KS
Katelyn Swindle-ReillyChief Technology Officer
MO
Matthew OhrChief Medical Officer
JS
Joe Seiwert IIIChief Product Development Officer
WE
Wayne EmbreeNamed on SEC filing
BB
Brad BeaseckerNamed on SEC filing
GC
Gary CharbonneauNamed on SEC filing
RS
Robin SearsNamed on SEC filing
BP
Brian PriceDirector CMC
GB
Gordon BethwaiteStrategic Sanint Consultant
Investors · 2
Competitors · 4
by search overlapVeratx4 shared keywordsVera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.
Ois4 shared keywordsOIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.
Arvinas Holding Co. LLC4 shared keywordsArvinas develops targeted protein degradation therapies using its PROTAC (PROteolysis TArgeting Chimeras) platform, which harnesses the body's natural protein disposal system to degrade disease-causing proteins. It focuses on treatments for cancers and other difficult-to-treat diseases, including targets considered "undruggable" by traditional approaches.
Healio3 shared keywordsHealio provides medical news, clinical data, and continuing medical education (CME) for healthcare professionals across specialties such as infectious disease and hepatology. It covers topics including biliary diseases, Ebola, and emerging outbreaks.
Companies competing with Vitranu for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements$1.5M disclosed across 1 round · 2021
▶$1.5MraisedOct 2021 · 13 investors · BiotechnologyRule 506(b)
▶$1.5MraisedOct 2021 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Wayne EmbreeDirector
- Gordon BethwaiteExecutive Officer, Director
- Brad BeaseckerExecutive Officer
- Gary CharbonneauDirector
- Robin SearsDirector
- Offering amount
- $3M
- Amount sold
- $1.5M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Vitranu do?
- Vitranu develops biomaterial and biologic technologies for ophthalmic applications, particularly focused on retinal and vitreoretinal diseases. The company brings medical devices and therapeutics to market for eye care professionals and patients.
- Who are Vitranu's investors?
- Vitranu's investors include JobsOhio Ventures, JumpStart Equity.
- How much funding has Vitranu raised?
- Vitranu has disclosed $1.5M raised across 1 round.
- Where is Vitranu headquartered?
- Vitranu is headquartered in Columbus, US.